… EGFR mutations. When undergoing EGFR‑TKI treatment, patients with rare EGFR mutations
… between particular rare EGFR mutations and EGFR-TKIs treatment outcomes is required. …

… In the efficacy analysis according to EGFR mutation type, the T790M … Our study confirms
the previous efficacy data of afatinib for NSCLC harboring uncommon EGFR mutations other …

… of the patient population most likely to derive benefit from EGFR TKIs, and to new trials in …
that the EGFR mutation status of a patient's tumor is predictive of gefitinib efficacy in Asian …

… or positive for EGFR mutation [19]. Until now, the relationship between the efficacy of
gefitinib and its pharmacokinetics and pharmacogenomics in patients with EGFR mutation-positive …

… erlotinib is superior to gefitinib in efficacy. The primary end … Finally, the efficacy data for erlotinib
and gefitinib indicated … superior to gefitinib in advanced NSCLC with EGFR exon 19 or 21 …

… the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC
patients with EGFR mutation. … of EGFR mutations in plasma in each visit during gefitinib re-…

… The aim of this study was to compare the effectiveness of gefitinib, erlotinib, and afatinib.
We retrospectively reviewed the records of 310 patients with the diagnosis of EGFR mutation-…

… icotinib and gefitinib had similar efficacy for brain metastasis of EGFR mutated NSCLC.
Large randomized studies are suggested to further illuminate the effect of these two EGFR-TKIs …

… with EGFR mutation positive. This study aims to compare the effectiveness of first line TKIs;
gefitinib, … stage NSCLC patients with EGFR mutation positive in the Indonesian population. …

… incidence of CNS failure compared with gefitinib or erlotinib after adjusting for both EGFR
mutation type and preexisting CNS metastases (HR 0.51, 95% CI, 0.34–0.75, P=0.0007). …